<DOC>
	<DOCNO>NCT00530660</DOCNO>
	<brief_summary>The purpose Phase II follow-up study ( study 810501 ) ass immunogenicity safety booster vaccination non-adjuvanted H5N1 influenza vaccine administer 12 17 month two-dose regimen different dos adjuvanted non-adjuvanted H5N1 influenza vaccine healthy young adult population . A data safety monitor board review safety data booster vaccination . The H5N1 influenza antibody persistence 180 day booster vaccination also assess .</brief_summary>
	<brief_title>Safety Immunogenicity Study Booster Vaccination With Non-Adjuvanted H5N1 Influenza Vaccine ( Follow Up Study 810501 )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects participate Study 810501 eligible participation study : Completed Day 42 visit study 810501 Have understanding study , agree provision , give write informed consent prior study entry Are clinically healthy , determine Investigator 's clinical judgment collection medical history performance physical examination Agree keep daily record symptom duration study If female capable bearing child , negative urine pregnancy test result study entry agree employ adequate birth control measure duration study Have history vaccination H5N1 influenza virus since second vaccination study 810501 Have allergic reaction one component vaccine since second vaccination Study 810501 Have diagnose significant neurological , cardiovascular , pulmonary ( include asthma ) , hepatic , rheumatic , autoimmune , hematological , renal metabolic disorder since second vaccination Study 810501 Are unable lead independent life result either physical mental handicap Suffer kind immunodeficiency since second vaccination Study 810501 Suffer disease undergo treatment within 30 day prior schedule booster vaccination currently undergoing form treatment expect influence immune response . Such treatment include , limited , systemic high dose inhale ( &gt; 800Âµg/day beclomethasone dipropionate equivalent ) corticosteroid , radiation treatment immunosuppressive cytotoxic drug Have severe allergic reaction anaphylaxis since second vaccination Study 810501 Have rash , dermatologic condition tattoo may interfere injection site reaction rating Have undergone systemic corticoid therapy within 30 day prior study entry Have functional surgical asplenia Have know suspect problem alcohol drug abuse Were administer investigational drug within six week prior study entry concurrently participate clinical study include administration investigational product Are member team conduct study dependent relationship study investigator . Dependent relationship include close relative ( i.e. , child , partner/spouse , sibling , parent ) well employee investigator If female , pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>46 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Pandemic influenza</keyword>
</DOC>